NASDAQ: DCTH - Delcath Systems, Inc.

半年間の収益性: +45.63%
配当利回り: 0.00%
セクタ: Healthcare

プロモーションスケジュール Delcath Systems, Inc.

詳細なスケジュール 簡易グラフ
Financial Markets by TradingView

会社について Delcath Systems, Inc.

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma.

さらに詳しく
The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
比較リストに追加
ウォッチリストに追加
ポートフォリオに追加
価格通知を追加

IPO date 2018-05-29
ISIN US24661P8077
Industry Health Care Equipment & Supplies
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.delcath.com
Цена ао 13.33
1日あたりの価格変動: -1.87% (13.4)
週ごとの価格変動: -4.15% (13.72)
月ごとの料金変更: -10.3% (14.66)
3ヶ月間の価格変動: +9.95% (11.96)
半年間の価格変動: +45.63% (9.03)
年間の価格変動: +175.68% (4.77)
3年間の価格推移: +108.07% (6.32)
5年間の価格推移: +19.44% (11.01)
年初からの価格変動: +10.6% (11.89)
すべてのパラメータ

過小評価

名前 意味 学年
P/S 10.93 1
P/BV 4.93 3
P/E 0 0
EV/EBITDA -25.25 0
合計: 3.38

効率

名前 意味 学年
ROA, % -45.81 0
ROE, % -62.44 0
合計: 0

配当金

名前 意味 学年
Div yield, % 0 0
DSI 0 0
合計: 0

義務

名前 意味 学年
Debt/EBITDA -0.0852 10
合計: 8.8

成長の衝動

名前 意味 学年
収益性 Revenue, % 1838.56 10
収益性 Ebitda, % -42 0
収益性 EPS, % -89.05 0
合計: 2.2
さらに詳しく

ETF共有, %年間の利益率, %配当金, %
iShares Micro-Cap ETF 0.0467 17.09 1.54048
0.0517.091.54



スーパーバイザー 役職 支払い 生年
Mr. Gerard J. Michel MBA, MS CEO & Director 727.97k 1963 (62 年)
Dr. Johnny John M.D. Senior Vice President of Clinical Operations & Medical Affairs 472.16k 1965 (60 年)
Ms. Sandra Pennell Senior VP of Finance and Principal Financial & Accounting Officer N/A 1980 (45 年)
Mr. David Hoffman General Counsel, Corporate Secretary & Chief Compliance Officer N/A
Dr. Martha S. Rook Ph.D. Chief Operating Officer N/A 1970 (55 年)
Dr. Vojislav Vukovic M.D., M.Sc., Ph.D. Chief Medical Officer 1967 (58 年)

住所: United States, New York. NY, 1633 Broadway - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.delcath.com